US5716832A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Packaging cells
Assignee: Oxford Biomedica UK Ltd
•
Filing: 1995-06-05
•
Granted: 1998-02-10
•
Expires: 2015-06-05
Abstract
Abstract The invention described herein allows the production of recombinant retroviruses (retroviral vector particles) from producer cells which are safer and of higher titre than normal. In addition, methods are provided for making helper cells which, when a recombinant retrovirus genome is introduced to make a producer line, produce particles that are targeted toward particular cell types. Methods are also provided for making recombinant retrovirus systems adapted to infect a particular cell type, such as a tumor, by binding the retrovirus or recombinant retrovirus in the particular cell type. Methods are also provided for producing recombinant retroviruses which integrate in a specific small number of places in the host genome, and for producing recombinant retroviruses from transgenic animals.
Inventors
- 👤 Jack R. Barber
- 👤 Douglas J. Jolly
- 👤 James G. Respess
- 👤 Stephen M. W. Chang
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 20:22
CPC Classifications
A; A01; A01K; A01K67/00; A01K67/027; A01K67/0275; C; C07; C07K; C07K14/00; C07K14/005; C07K14/435; C07K14/705; C07K14/70503; C07K14/70514; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N15/8509; C12N15/86; C12N7/00; A01K2217/00; A01K2217/05; A01K2217/30; A01K2227/00; A01K2227/10; A01K2227/105; A01K2267/00; A01K2267/01; A61; A61K; A61K39/00; A61K2039/51; A61K2039/525; A61K2039/5256; A61K2039/53; A61K2039/57; A61K48/00; C07K2319/00; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/11011; C12N2740/11041; C12N2740/11043; C12N2740/11051; C12N2740/11052; C12N2740/13011; C12N2740/13022; C12N2740/13023; C12N2740/13041; C12N2740/13043; C12N2740/13051; C12N2740/13052; C12N2740/15011; C12N2740/15022; C12N2740/16011; C12N2740/16023; C12N2740/16211; C12N2740/16222; C12N2830/00; C12N2830/008
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
75 words
A method of producing a recombinant retrovirus, comprising growing a producer cell having a genome comprising: (a) a gene of interest and a packaging signal of a first retrovirus; (b) gag and pol genes of the first retrovirus, absent a packaging signal; (c) a hybrid env gone absent a packaging signal, the product of said hybrid env gone comprising a cytoplasmic segment of the first retrovirus, and a binding segment exogenous to the first retrovirus.
Claim 2
Independent Claim
75 words
A method of producing a recombinant retrovirus, comprising growing a producer cell having a genome comprising: (a) a gene of interest and a packaging signal of a first retrovirus; (b) gag and pol genes of the first retrovirus, absent a packaging signal; (c) a hybrid env gone absent a packaging signal, the product of said hybrid env gone comprising a cytoplasmic segment of the first retrovirus, and a binding segment exogenous to the first retrovirus.
Claim 3
Dependent Claim
20 words
A xenotropic packaging cell line which, upon introduction of a vector construct, produces viral particles uncontaminated by replication competent virus.
Claim 4
Dependent Claim
20 words
A xenotropic packaging cell line which, upon introduction of a vector construct, produces viral particles uncontaminated by replication competent virus.
Claim 5
Dependent Claim
34 words
The packaging cell line of claim 2 wherein the cell line produces at least equal vector titre as compared to a standard mouse amphotropic packaging cell line PA 317 when HT1080 cells are infected.
Claim 6
Dependent Claim
20 words
A polytropic packaging cell line which, upon introduction of a vector construct, produces vital particles uncontaminated by replication competent virus.
Claim 7
Dependent Claim
20 words
A polytropic packaging cell line which, upon introduction of a vector construct, produces vital particles uncontaminated by replication competent virus.
Claim 8
Dependent Claim
44 words
The packaging cell line of claim 4 wherein the packaging cell line, upon introduction of a vector construct, produces at least a ten-fold increase in vector titre as compared to a standard measure amphotropic packaging cell line PA 317 when 293 cells are infected.
Claim 9
Dependent Claim
35 words
A polytropic packaging cell line wherein the packaging cell line, upon introduction of a vector construct, produces viral particles which infect cells of kidney lineage, but not cells or fibreblast, epithelial, T-cell or monocyte lineage.
Claim 10
Dependent Claim
35 words
A polytropic packaging cell line wherein the packaging cell line, upon introduction of a vector construct, produces viral particles which infect cells of kidney lineage, but not cells or fibreblast, epithelial, T-cell or monocyte lineage.
Claim 11
Dependent Claim
43 words
A non-mouse packaging cell the carrying on separate operons the genes for gag/pol and env, said operons lacking retroviral LTR sequences and which, upon introduction of an N2 type vector construct, produces no helper virus after at least twenty days passage in culture.
Claim 12
Dependent Claim
43 words
A non-mouse packaging cell the carrying on separate operons the genes for gag/pol and env, said operons lacking retroviral LTR sequences and which, upon introduction of an N2 type vector construct, produces no helper virus after at least twenty days passage in culture.
Claim 13
Dependent Claim
16 words
The cell line of claim 7 wherein the cell line is an amphotropic packaging cell line.
Claim 14
Dependent Claim
16 words
The cell line of claim 7 wherein the cell line is a polytropic packaging cell line.
Claim 15
Dependent Claim
16 words
The cell line of claim 7 wherein the cell line is a xenotropic packaging cell line.
Claim 16
Independent Claim
106 words
A method of producing a recombinant retrovirus, comprising: (a) introducing packaging genes from a retroviral vector system into a cell line, said cell line having no endogenous proviruses which produce transcripts packageable by the retroviral vector system; (b) selecting for cells that produce at least a ten-fold increase in viral packaging protein as compared to a standard mouse amphotropic packaging cell line PA317, and that, upon introduction of a vector construct, produce at least a ten-fold increase in vector titre as compared to a standard mouse amphotropic packaging cell line PA317; and (c) growing the cells selected in step (b) such that recombinant retrovirus is produced.
Claim 17
Independent Claim
106 words
A method of producing a recombinant retrovirus, comprising: (a) introducing packaging genes from a retroviral vector system into a cell line, said cell line having no endogenous proviruses which produce transcripts packageable by the retroviral vector system; (b) selecting for cells that produce at least a ten-fold increase in viral packaging protein as compared to a standard mouse amphotropic packaging cell line PA317, and that, upon introduction of a vector construct, produce at least a ten-fold increase in vector titre as compared to a standard mouse amphotropic packaging cell line PA317; and (c) growing the cells selected in step (b) such that recombinant retrovirus is produced.
References Cited (Backward Citations)
US4650764A
Cited
WO1986000922A1
Cited
US4861719A
Cited
US5126433A
Cited
WO1988008454A1
Cited
US4980289A
Cited
WO1989002468A1
Cited
WO1989002797A1
Cited
US5278056A
Cited
WO1989009271A1
Cited
WO1990002806A1
Cited
US5124263A
Cited
EP0386882A1
Cited
WO1991002805A2
Cited
WO1993000103A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-02-09 | 2001-08-11 | 2002-02-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-02-09 | 2005-08-11 | 2006-02-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-02-09 | 2009-08-11 | 2010-02-10 | $7700.00 | Window Closed / Lapsed |